{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:42:48Z","timestamp":1775522568398,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ijantimicag.2019.11.006","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T11:15:56Z","timestamp":1574507756000},"page":"105849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data"],"prefix":"10.1016","volume":"55","author":[{"given":"J. Nicholas","family":"O'Donnell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel J.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren R.","family":"Biehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Esterly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Twisha S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena M.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0001","series-title":"Antibiotic resistant threats in the United States, 2013","year":"2013"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0002","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0003","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ndt\/gfm744","article-title":"A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients","volume":"23","author":"Bagshaw","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0006","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00134-008-1367-2","article-title":"Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy","volume":"35","author":"Bagshaw","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0007","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/01.CCM.0000277041.13090.0A","article-title":"Acute kidney injury in the intensive care unit according to RIFLE","volume":"35","author":"Ostermann","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime\u2013avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0009","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem\u2013vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijantimicag.2016.01.004","article-title":"In vitro activity of ceftazidime\/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients","volume":"47","author":"Flamm","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0011","article-title":"Emergence of ceftazidime\u2013avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0012","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime\u2013avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0013","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jac\/dkr156","article-title":"Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae","volume":"66","author":"Patel","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0014","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/14787210.2016.1159131","article-title":"Carbapenem susceptibility breakpoints, clinical implications with the moving target","volume":"14","author":"O'Donnell","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0015","series-title":"Summary of WG Meeting to AST SC Jan 25, 2010","author":"Dudley","year":"2010"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0016","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2009.02.004","article-title":"Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem","volume":"64","author":"Weisenberg","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0017","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1086\/505598","article-title":"The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York","volume":"43","author":"Lomaestro","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0018","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143845","article-title":"Outcomes and risk factors for mortality among patients treated with carbapenems for Klebsiella spp. bacteremia","volume":"10","author":"Biehle","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0020","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.06365-11","article-title":"Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification","volume":"56","author":"Esterly","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.03057-14","article-title":"Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs","volume":"53","author":"Patel","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2334-14-31","article-title":"Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes","volume":"14","author":"McLaughlin","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0023","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/AAC.06301-11","article-title":"Carbapenem therapy for bacteremia due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility","volume":"56","author":"Lee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.006_bib0024","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/cid\/ciw201","article-title":"Emerging resistance, new antimicrobial agents... but no tests! The challenge of antimicrobial susceptibility testing in the current US regulatory landscape","volume":"63","author":"Humphries","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919303206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919303206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:30Z","timestamp":1760376810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919303206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0924857919303206"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.11.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105849"}}